

3 December 2015

Australian Securities Exchange Level 40, Central Park 152-158 St George's Terrace Perth WA 6000

ALCIDION CORPORATION INVESTOR PRESENTATION

Please find enclosed an Investor Presentation that will be given by Mr Nathan Buzza today at the Blue Sky Private Equity Investor Conference.

Sincerely,

Josh Puckridge

Director

Naracoota Resources Limited

+61 (0) 452 440 100





FORWARD LOOKING STATEMENTS

- This presentation contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or "recurring" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved.
- Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as competition, technological changes, the changing needs of hospitals, the financial condition of Alcidion's current and potential customers, foreign currency exchange rates, as well as general economic conditions, which may cause the actual results, performance or achievements of Alcidion to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this presentation.
- There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

 Accordingly, readers should not place undue reliance on forward-looking statements.
- Neither Alcidion Corporation nor Naracoota Resources Limited (ASX:NRR) accepts responsibility for the adequacy or accuracy of this presentation.





OPPORTUNITY OVERVIEW

- Alcidion is a medical informatics company, based in Adelaide that has invested in excess of \$15m in the Research & Development of a Clinical Decision Support platform.
- The technology is already deployed and operational at Western Health, Northern Territory Health Department and Tasmania Health and the Royal Melbourne.
- Management team includes:
 - Former Chief Executive of the South Australia Health Commission
 - Physician with a PhD in Medical Informatics from Stanford University.
 - Former Ernst & Young "Entrepreneur of Year"
- Initial Seed Capital provided by BlueSky Private Equity and Venture Capital firm, Allure Capital.
- Recently announced the Reverse Takeover (RTO) of Naracoota Resources (ASX:NRR), with shareholders voting on December 21st 2015 to approve the transaction.
- Fully Funded with \$7m in cash post RTO, debt free.
- Founders retain high level of shareholding post RTO and fully committed to commercializing the company.





ALCIDION CORPORATION EXECUTIVE SUMMARY

Company	Alcidion Corporation Pty Ltd	
Structure	Privately Held	
Revenues	\$5.05m (FY15), Audited	
EBITDA	\$183k Loss (FY15), Audited	
Enterprise Valuation	\$10.50m (\$1.50m Working Capital), Audited	
Employees	39 x FTE, 2 x Contractors	
R&D Investment	~\$15m, Unaudited	
Market	Acute Care Hospitals	
GICS	Health Care Equipment & Services	
Product Set	Miya ED Miya Patient Flow Miya Clinic	
Prior Funding	\$2.00m Blue Sky Private Equity \$1.50m BSPE, Allure Capital, Founders \$3.16m Grant Funding. \$3.12m R&D Tax Concession	





ALCIDION OVERVIEW

- Alcidion is a provider of intelligent informatics for high performance healthcare – safer for patients because clinicians are alerted to clinical risk, faster delivery of care because service barriers are identified and improved productivity because clinicians save time in accessing key data and documenting their decisions and observations.
- By providing clinicians with decision support tools and prompting care guidance in accordance with hospital approved clinical protocols, patient clinical outcomes may be improved.
- Alcidion's solutions target key problems for:
 - Emergency Departments
 - Inpatient Services
 - Outpatient Departments
- Alcidion's Miya Platform is built upon a health informatics infrastructure, which includes an intelligent EMR, Clinical Decision Support Engine & Electronic Smartforms.





BOARD OF DIRECTORS



Chief Medical Officer Prof. Malcolm Pradhan

- Formal qualifications in medicine complimented by a PhD in Medical Informatics from Stanford University.
- Founding fellow of the Australasian College of Health Informatics.
- Associate Dean of IT &
 Director of Medical
 Informatics at the University of Adelaide.
- Clinical Lead within the Australian Government's National e-Health Transition Authority.



Chief Executive Officer Mr. Ray Blight

- Formal qualifications include a Bachelor of Technology, Bachelor of Economics and a MBA.
- Former CEO of the South Australian Health Commission and Chair of the Health Ministers' Advisory Council
- Consultant to the World Bank.
- Chairs the University of SA IT & Mathematical Sciences Advisory Board.



Executive Director Mr. Nathan Buzza

- Former CEO of Commtech Wireless.
- EY "Entrepreneur of the Year" in both 2002 & 2005.
- BRW in the "Fast100", for three consecutive years.
- WA IT & telecommunications Life Time achievement Award for contribution to the IT community.
- Previously the second largest shareholder of Azure Healthcare (<u>ASX:AZV</u>).



Non-Executive Director Mr. Alex McNab

- Formal qualifications include a MBA & Bachelor of Economics and a Bachelor of Law.
- Director of BlueSky
 (ASX:BAF), a listed alternative
 asset manager with \$1b of
 assets under management.
- Responsible for all aspects of the investment process, including deal origination, due diligence, executing transactions and working with portfolio companies.
- Alex joined Blue Sky from Bain & Company.




TRANSACTION HIGHLIGHTS

Acquirer	Naracoota Resources Ltd (ASX:NRR)
Alcidion Overview	Alcidion is a provider of advanced informatics software for high performance healthcare.
Transaction	 100% acquisition of Alcidion for \$12m in initial scrip consideration and a further: \$4m in scrip on achieving \$10m in revenue within 2 years and; \$4m in scrip on achieving \$15m in revenue within 3 years.
Market Opportunity	 Global expenditure in Healthcare IT is currently US\$40.4b and anticipated to grow to US\$56.7b by 2017. Obama Care incentivises US hospitals to adopt decision support technology – as is the Miya Platforms– and this will be a focus of growth. 96.3% of US Hospitals have not achieved Level 7, EMRAM certification (fully electronic / paperless hospital).
Proven Technology	 Alcidion's platforms currently operate in 11 Australian hospitals. Processing hundreds of thousands of clinical message annually.
Strong Balance Sheet	 Debt Free Cash Balance of \$7.00m post closing. Positive Working Capital of \$6.75m post closing.
Transaction	 Highly favourable 2.05x Enterprise Value / Revenue. Alcidion Shareholders retain 64.22% of NRR Post RTO.





OWNERSHIP STRUCTURE POST LISTING





TRANSACTION HIGHLIGHTS

- Capable & Experienced Management Team, with a strong track record of commercializing healthcare software.
- The platform is at the forefront of technology, on the crest of the next generation of healthcare technologies.
- Proven technology platform, with established commercialization strategy – funding to be applied to accelerate commercialization strategy.
- The Miya platform has been successfully deployed broadly across a number of very large healthcare organizations, including:
 - Footscray Hospital, Sunshine Hospital & Williamstown
 - Royal Darwin Hospital, Alice Springs Hospital
 - Tasmania Health Department
- The investment will enable Alcidion to capitalize on the rapidly expanding Healthcare IT market.
- Highly favourable transactional terms, coupled with a strong alignment of the shareholders to grow the business domestically and internationally.





ALCIDION MULTIPLE KEY DRIVERS OF MARKET GROWTH

Customer Demand

- Increased cost pressure drives the need to quantifiable ROI.
- Demand for systems drives base of service growth.
- Ongoing regulatory requirements (ISO, FDA, MDD, MMA).
- Patient Satisfaction / Safety.
- Clinician Satisfaction / Safety.
- Workflow & Bed Management.
- Healthcare Group Consolidation, driving standardization across healthcare.
- Ward Pull versus Ward Push.
- Growing market opportunity for Clinical Decision Support and Mobility Solutions within healthcare.
- Growing Incidences of Medication Errors
- Requirement to meet the criteria of "Meaningful Use" to receive incentives by the US Federal Government encourage the adoption of EHR

Technology

- Growing demand for integrated Clinical Decision Support Solutions with EHR and CPOE.
- Technological revolution in Clinical Connectivity.
- Rising demand for analytical solutions.



A growing market for Clinical Decision Support



Challenges

- Growing concerns over security.
- Integration challenges.
- Costs incurred while integrating.
- Alert fatigue.
- Fragmented End-User Market

Demographics / Economy

Demographics

- Rise in ageing population
- Longer life expectancy
- Growth in comorbidities
- Elderly people stay off site

Regional Trends

- USA, APAC & Latin America economic growth triggers new Capital Expenditure.
- Growth in patient consumerism for quality care

Economic Cycle

• Series of recessions.

• Cost Pressure in Health care:

- Government initiatives that promote the adoption of Clinical Decision Support.
- Increase focus on work efficiency.
- Shortage of clinicians.



US EMR ADOPTION MODEL CURRENT STATUS

US EMR Adoption ModelSM

Stage	Cumulative Capabilities	2015 Q1	2015 Q2
Stage 7	Complete EMR; CCD transactions to share data; Data warehousing; Data continuity with ED, ambulatory, OP	3.7%	3.7%
Stage 6	Physician documentation (structured templates), full CDSS (variance & compliance), full R-PACS	22.2%	23.6%
Stage 5	Closed loop medication administration	30.8%	32.3%
Stage 4	CPOE, Clinical Decision Support (clinical protocols)	13.6%	13.2%
Stage 3	Nursing/clinical documentation (flow sheets), CDSS (error checking), PACS available outside Radiology	19.7%	18.2%
Stage 2	CDR, Controlled Medical Vocabulary, CDS, may have Document Imaging; HIE capable	4.3%	3.6%
Stage 1	Ancillaries - Lab, Rad, Pharmacy - All Installed	2.2%	1.9%
Stage 0	All Three Ancillaries Not Installed	3.5%	3.3%





MARKET OPPORTUNITY

- Clinical Decision Support Systems integrate patient data with a knowledge-base to produce patient specific output in the form of care guidance, assessments, alerts and reminders.
- President Obama's administration has pledged to give every American an electronic health record within five years, arguing that this is "fundamental to reforming" the entire healthcare system.
- In 2009, the US government released \$1.2 billion to help healthcare providers implement and use Electronic Medical Records.
- The US government has legislated that hospitals must deploy at a minimum one component of a CDSS by 2016.
- The HITECH Act stipulates that healthcare providers must demonstrate the meaningful use of health IT by 2015 or face a reduction in Medicare reimbursements.






MARKET OPPORTUNITY

- Global expenditure on Healthcare IT is \$USD40.4b, growing to \$USD56.7b by 2017.
- Mobile Healthcare technology is growing from \$USD6.9b market in 2014 to \$USD23b market by 2017.
- The Clinical Decision Support Systems Market is set to grow 21.5% CAGR from \$USD1.18b in 2013 to \$USD4.65b by 2018 (IndustryARC)
- One third of all hospitals in the USA are planning to invest in Patient Flow Solutions this year alone (Capsite, division of HIMSS).
- Alarm Fatigue identified as the #1 Patient Safety Objective by the Joint Commission in 2014
- Geographic analysis reveals that the US was the largest contributor to the global Clinical Decision Support Market in 2013 and will also be the fastest growing region for Clinical Decision Support.
- Alcidion has invested in excess of \$15m in developing a product suite based on a Clinical Decision Support platform, positioning Alcidion to capitalize on the emerging opportunity.




12 MONTH INDEX PERFORMANCE







5 YEAR INDEX PERFORMANCE









- An E-Health guidance system:
 - Designed to consolidate clinical information and other patient data from multiple sources across the hospital
 - Focused on patient clinical risk and providing guidance on options to mitigate that risk
 - Providing fast, ubiquitous access across the hospital via desktop web portals, large digital displays (Journey Boards) and iPads at the point of care
- Pushes risk rated clinical information to the care team.
- Aimed at making visible the key points of patient information necessary to plan for care
- Supportive of emerging BYOD trends as the industry transitions to Smartphones and tablets.





ALCIDION'S MIYA PLATFORM

PAS HL7 Admit, Discharge, Transfer Administrative PAS HL7 Patient Demographics PAS Export Elective Admissions Emergency IS Patients, Admit Requests Laboratory Results Clinical RIS Orders, Bookings **PACS Images Active Directory** Roles, Users

Journey Board

Data Integration, Analysis, e-Guidance

Miya Platform

Mobility










MIYA OVERVIEW






PRODUCT OFFERING



Build a team based approach to managing clinical risk





Create a safer, more efficient patient journey.





Mitigate risks and streamline your Outpatient Department

Referral Management System

Clinical Dashboards

Miya Smartforms®

Results Management

